English
Regional settings| Spread | 0.0125 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ US$5,000.00 Short position overnight fee ~ US$4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
Information_provided_by_capital
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.1745 |
| Open | 0.1665 |
| 1-Year Change | -93.87% |
| Day's Range | 0.1665 - 0.2026 |
Galera Therapeutics, Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing a pipeline of therapeutics to transform radiotherapy in cancer. The Company's lead product candidate, avasopasem manganese (GC4419), is a potent and selective small molecule dismutase mimetic, which is developed for the reduction of severe oral mucositis (SOM). It is also developing a second dismutase mimetic product candidate, GC4711, to increase the anti-cancer efficacy of stereotactic body radiation therapy (SBRT). It is evaluating GC4419 in a Phase III registrational trial (ROMAN trial) to reduce the incidence and severity of SOM induced by radiotherapy in patients with head and neck cancer (HNC), its lead indication. The Company is also evaluating GC4711 in combination with SBRT in a Phase I/II safety and anti-cancer efficacy trial in non-small cell lung cancer and a Phase IIb trial of GC4711 in combination with SBRT in patients with pancreatic cancer.
BRIEF: For the fiscal year ended 31 December 2021, Galera Therapeutics Inc revenues was not reported. Net loss increased 9% to $80.5M. Higher net loss reflects General and administrative - Balancing increase of 32% to $16.6M (expense), Interest expense increase of 47% to $7.2M (expense), Stock-based Compensation in SGA increase of 40% to $4.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$2.98 to -$3.12.
